#
Progress Update: Regulation and activity of the DUX4 transcription factor
May 20, 2020
Dr. Tapscott provides an update on his multi-year grant.
#
Progress Update: Antisense Oligonucleotide – Antibody Conjugates to Treat FSHD
May 20, 2020
Dr. Marusak provides an update on progress so far.
#
Dyne Therapeutics Accelerates Programs in FSHD
May 19, 2020
Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization University of Mons
#
Fulcrum Therapeutics Update on ReDUX4 Study
May 13, 2020
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.